TCR V beta 8a Monoclonal Antibody (16G8), FITC, Invitrogen™

Description

• TCR2648 targets TCR V beta 8a in FACS, IHC(F), IP, TCA, and WB applications and shows reactivity with Human, and Non-human primate samples
• The TCR2648 immunogen is human TCR V beta 8
• The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response
• TCR recognition of self-peptides has been linked to autoimmune disease
• Mutant self-peptides have been associated with tumors
• Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome
• Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
• The autoantibodies block TH1-mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for disease (ref5)
• T Cell and TCR Diversity Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP)
• A small number of T cells lack both CD4 and CD8 (double negative, DN)
• Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders
• Gamma-delta T cells are primarily found within the epithelium
• They show less TCR diversity and recognize antigens differently than alpha-beta T cells
• Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.